Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2044

Annual patent cliff calendar for 2044 — US pharmaceutical patents by expiration date.

Patents
1,766

Quick answer

1,766 indexed pharmaceutical patents have expiration dates in 2044. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 12049630

    Factor XII (F12) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12049670

    Proprotein convertase subtilisin/kexin type 1 (PCSK1) variants and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12049464

    Compounds for targeted degradation of BRD9

    C4 THERAPEUTICS, INC. · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12049520

    Bicyclic peptide ligands specific for CD137

    BicycleTx Limited · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12048747

    Substituted piperidine Degronimers for Target Protein degradation

    C4 THERAPEUTICS, INC. · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12048687

    Methods of recruiting SDF-producing macrophages

    MedRegen, LLC · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12049489

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12049505

    Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof

    CytomX Therapeutics, Inc. · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12049510

    Chimeric antigen receptor

    AUTOLUS LIMITED · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12049642

    Corneal endothelial cells with increased cell density and compositions thereof

    Astellas Institute for Regenerative Medicine · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12049645

    Differentiation of pancreatic endocrine cells

    Vertex Pharmaceuticals Incorporated · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12049652

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12049628

    Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases

    Alnylam Pharmaceuticals, Inc. · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. IT 202300001434

    PRODOTTO DI FERMENTAZIONE PER USO NEL TRATTAMENTO DI PATOLOGIE ASSOCIATE ALLA SINDROME METABOLICA E STEATOSI EPATICA.

    ALFASIGMA SPA [IT] · Granted Thu Aug 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jul 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12054483

    Small molecule inhibitors of DYRK/CLK and uses thereof

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12054758

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12054557

    Combination of anti-PD-1 antibodies and bispecific anti-CD20/anti-CD3 antibodies to treat cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12054517

    Myeloid differentiation factor 2 (MD2) signaling and modulation

    The Regents of the University of California · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12053491

    Bispecific OR-gate chimeric antigen receptor responsive to CD19 and CD20

    The Regents of the University of California · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12053477

    Methods for treating pulmonary fibrosis

    REVIVA PHARMACEUTICALS, INC. · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 12053513

    Cancer-specific T-cell receptors

    University College Cardiff Consultants Limited · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 12053526

    Methods for treatment using anti-alpha4beta7 antibody

    Takeda Pharmaceutical Company Limited · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 12053520

    Glycan-masked engineered outer domains of HIV-1 gp120 and their use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 12053569

    Indwelling intravascular aphaeretic system for in vivo enrichment of circulating tumor cells

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 12053619

    Intradermal jet injection electroporation

    Inovio Pharmaceuticals, Inc. · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 12054474

    Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases

    Takeda Pharmaceutical Company Limited · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 12054475

    Substituted heterocycles as aldehyde dehydrogenase inhibitors

    THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 12054492

    Imidazole-containing inhibitors of ALK2 kinase

    BioCryst Pharmaceuticals, Inc. · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 12053494

    Compositions comprising nanoparticles, method of making and uses thereof

    ORGANICELL REGENERATIVE MEDICINE, INC. · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 12054718

    RNAi agents for inhibiting expression of PNPLA3, pharmaceutical compositions thereof, and methods of use

    Arrowhead Pharmaceuticals, Inc. · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 12054487

    Muscarinic acetylcholine M1 receptor antagonists

    Contineum Therapeutics, Inc. · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 12054500

    Arginase inhibitors

    Arcus Biosciences, Inc. · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 12054509

    Antimicrobial compounds, compositions, and uses thereof

    Lakewood Amedex, Inc. · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 12054501

    Compositions and methods for inhibiting arginase activity

    Precision Pharmaceuticals, Inc. · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 12054537

    Optimized nucleic acid antibody constructs encoding anti-respiratory syncytial virus (RSV) antibodies

    Inovio Pharmaceuticals, Inc. · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 12054553

    Immunotherapeutic tumor treatment method

    Nektar Therapeutics · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 12054556

    Anti-PD-L1 antibody and use thereof

    Oricell Therapeutics Co., Ltd. · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 12054533

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 12054519

    Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes

    The United States of America as Represented by the Secretary, Dept. of Health and Human Services · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 12054744

    NK cells exhibiting an adaptive phenotype and methods for preparing and for using

    Regents of the University of Minnesota · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 12054749

    Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 12054607

    Tough, healable composites displaying stress relaxation at the resin-filler interface

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 12055553

    Method for diagnosing risk for inflammatory disease through glycan profiling

    The Regents of the University of California · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 12053519

    HIV-1 Env fusion peptide nanoparticle carrier conjugates and their use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 12053481

    Compositions and methods for deep dermal drug delivery

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 12053444

    Therapeutic compounds, formulations, and uses thereof

    Tvardi Therapeutics, Inc. · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 12053455

    Antigen-driven detection and treatment of coccidioidomycosis

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 12053511

    Cystatin C and Cystatin 9 to treat gut inflammation caused by thermal injury

    Boards of Regents, The University of Texas System · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2044?

1,766 published patents in our USPTO index have expiration dates falling in calendar year 2044.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.